Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Accumulated Expenses (2019 - 2026)

Summit Therapeutics filings provide 8 years of Accumulated Expenses readings, the most recent being $7.1 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 60.9% to $7.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Mar 2026, up 60.9% year-over-year, with the annual reading at $32.1 million for FY2025, 64.16% up from the prior year.
  • Accumulated Expenses hit $7.1 million in Q1 2026 for Summit Therapeutics, down from $32.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $32.1 million in Q4 2025 and bottomed at $1.9 million in Q2 2022.
  • Average Accumulated Expenses over 5 years is $10.9 million, with a median of $7.6 million recorded in 2022.
  • The largest annual shift saw Accumulated Expenses crashed 68.92% in 2022 before it surged 436.15% in 2025.
  • Summit Therapeutics' Accumulated Expenses stood at $10.7 million in 2022, then plummeted by 49.09% to $5.4 million in 2023, then surged by 260.18% to $19.6 million in 2024, then surged by 64.16% to $32.1 million in 2025, then tumbled by 77.97% to $7.1 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Accumulated Expenses are $7.1 million (Q1 2026), $32.1 million (Q4 2025), and $11.0 million (Q3 2025).